1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited

780.70
INR
-7.45
(-0.95%)
33.53EPS
24.47P/E
162.16BMarket Cap
Nov 10Next Earn
Alembic Pharmaceuticals Limited
BSE:APLLTD
(Bombay Stock Exchange)

Recent

price

780.70

P/E

ratio

24.47

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
63.77
75.96
79.24
96.53
106.63
161.06
160.73
161
201.93
238.28
272.33
266.16
279.8
310.95
332.7
366.94
385.67
Revenue per Share
4.53
6.9
8.77
12.49
15.01
38.2
21.39
21.89
31
43.97
59.18
26.5
17.4
31.33
29.68
34.33
33.72
Basic EPS, GAAP
1.72
4.27
9.49
8.38
-2.11
34.3
-9.63
-27.02
37.21
-18.46
41.49
6.45
14.27
24.2
-24.2
14.64
- -
Free Cash Flow per Basic Share
- -
1.15
1.61
2.89
3.47
4.17
4.78
4.81
4.82
17.29
- -
14
10
8
11
11
- -
Dividend per Share
15.74
20.95
26.68
35.84
51.15
84.73
100.91
117.77
144.22
170.78
260.86
266.46
222.34
245.12
264.09
288.7
- -
Book Value per Share
15.74
20.95
26.68
35.84
51.15
84.73
99.48
108.98
129.91
154.91
244.39
258.58
222.34
245.12
264.09
274.11
- -
Tangible Book Value per Share
188
189
188
189
188
189
189
189
189
189
194
197
197
197
197
197
197
Basic Weighted Avg Shares
12,020
14,327
14,931
18,201
20,100
30,362
30,301
30,350
38,066
44,920
52,762
52,318
54,998
61,121
65,397
72,126
75,845
Sales/Revenue/Turnover
10.95
13.42
14.33
17.64
17.57
30.84
17.82
16.8
19.8
24.73
24.58
11.33
8.07
10.86
11.24
11.15
10.47
Operating Margin (%)
296
336
350
405
444
722
830
1,055
1,152
1,573
1,835
2,868
2,754
2,727
2,786
3,186
3,402
Depreciation Expense
854
1,301
1,653
2,355
2,829
7,200
4,032
4,126
5,844
8,288
11,465
5,209
3,420
6,158
5,834
6,748
6,631
Net Income, GAAP
20.08
19.16
19.92
24.18
21.26
23.09
23.09
22.23
20.92
19.92
18.52
16.7
3.56
2.53
17.7
3.33
4.71
Effective Tax Rate (%)
7.1
9.08
11.07
12.94
14.08
23.72
13.31
13.6
15.35
18.45
21.73
9.96
6.22
10.08
8.92
9.36
8.74
Profit Margin (%)
1,392
1,527
1,905
2,541
3,301
7,641
6,798
6,804
4,681
7,112
13,712
11,443
12,731
16,236
16,755
19,488
- -
Working Capital
1,285
949
705
522
188
- -
- -
5,000
4,993
9,603
2,714
721
692
629
468
1,667
- -
LT Debt
2,967
3,950
5,029
6,756
9,643
15,974
19,024
22,205
27,180
31,905
50,670
52,376
43,705
48,182
51,895
56,690
- -
Total Equity
- -
23.79
24.44
33.51
27.92
48.87
22.24
16.3
17.39
18.4
19.91
8.49
7.63
12.5
10.48
10.52
- -
Return on Invested Capital (%)
- -
24.33
25.66
33.01
28.59
49.1
21.86
16.88
17.71
19.82
22.32
9.66
7.07
12.87
11.03
11.36
- -
Return on Capital (%)
- -
37.63
36.81
39.97
34.51
56.22
23.04
20.02
23.66
27.91
27.47
10.05
7.12
13.4
11.66
12.42
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
12,633
- -
LT Borrowings
- -
1,219
- -
LT Finance Leases
- -
448
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
197
197
197
Market Capitalization
166,725
130,095
162,165

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
45,426
- -
Cash, Cash Equivalents & STI
- -
2,166
- -
Accounts Receivable, Net
- -
14,663
- -
Inventories
- -
25,106
- -
Total Current Liabilities
- -
25,938
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
12,633
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.84%
2.8%
9.24%
Free Cash Flow
-91.97%
-50.75%
-160.52%
Net Income, GAAP
8.17%
0.31%
15.66%
Sales/Revenue/Turnover
9.35%
6.54%
10.29%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
15,617
16,480
16,927
17,696
65,397
2026
17,107
- -
18,763
18,477
72,126
2027
21,498
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
6.84
7.79
7.01
7.98
29.68
2026
7.85
- -
6.76
10.31
34.33
2027
8.8
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
11
2026
- -
- -
- -
- -
11
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Alembic Pharmaceuticals Limited (Alembic Pharma) manufactures and markets a broad portfolio of pharmaceutical products including active pharmaceutical ingredients (APIs), domestic formulations, international generics, and animal health products; its offerings span therapeutic areas such as cardiology, dermatology, diabetes, ophthalmology, infectious diseases, gastroenterology, oncology, orthopedics, anti-infectives, anti-diabetics, gynecology, and treatments for cold and cough, with branded generics like Althrocin (erythromycin) and specialized formulations including oral solids, injectables, ophthalmics, oncology medicines, and dermatology products; the company also produces animal health formulations such as Sharkoferrol (oral hematinic), Moxel Inj (amoxicillin and cloxacillin), Xceft Inj (ceftiofur sodium), and Mceft Inj (ceftizoxime sodium). Founded in 1907 and headquartered in Vadodara, Gujarat, India, Alembic Pharma operates manufacturing facilities in Panelav, Karakhadi, Jarod, and Sikkim in India, plus Pithampur in Madhya Pradesh, with research and development centers in Vadodara, Hyderabad (India), and New Jersey (USA); it generates approximately 40% of revenues from the US generics market (with over 250 ANDA filings and 223 approvals as of mid-2025), 30% from India formulations reaching 1.75 lakh doctors via 17 marketing divisions, 18% from third-party API sales, and the balance from other international markets including Europe, China (via joint venture), Algeria, Australia, Brazil, and over 90 countries globally. Recent developments include the July 2025 acquisition of UK-based Utility Therapeutics Ltd. by its US subsidiary for $12 million, securing FDA-approved branded product Pivya (pivmecillinam) for uncomplicated urinary tract infections with commercialization planned for Q4 2025, marking entry into the US specialty branded market; in April 2025, the company commissioned a Rs 205 crore formulations facility in Pithampur to enhance in-house production and supply chain efficiency; FY25 saw 16 new US product launches (including 9 oral solids, 2 injectables, 2 ophthalmics, 3 dermatology), US FDA approvals for generics like Rivaroxaban (Xarelto), Amlodipine-Atorvastatin (Caduet), Doxorubicin Liposome (Doxil), Tretinoin Cream (Retin-A), and Olopatadine Ophthalmic (Pataday), plus a 2024 strategic distribution agreement with Amlan International for poultry feed additives via its Animal Health Division.